The Neoleish vaccine, with the participation of the Margarita Salas Biological Research Centre (CIB-CSIC), prevents infection and reduces the presence of the parasite by more than 90%.

Two new patents developed at the Institute of Advanced Chemistry of Catalonia (IQAC) from the CSIC have been licensed by Bicosome company. The new technological platforms made of only lipids and water do not need the presence of polymers, surfactants, or other gelling agents, bringing valuable benefits for skin care, especially sensitive skin.

The antibody acts on the immune system to increase anti-inflammatory activity and attenuate inflammation. It will be developed by the Inhibitec Anticuerpos company, created by the scientists who created the technology at the CSIC and the University of Cantabria.

Researchers from the Institute of Materials Science of Barcelona (ICMAB-CSIC) and B. Braun Surgical, a leading manufacturer of medical devices for wound closure, have collaborated to develop a bio-based surgical mesh with this biomaterial. First results from an in vivo animal study yield promising outcomes.

This is one of the major achievements of the European Smart4Fabry project, which is now coming to an end after four years of work. The results have been made possible by nanotechnology and the approach developed could be applied to other drugs in the future. The new drug improves on current treatments and helps reduce costs and improve patients' quality of life.

A new serological test for Covid-19 with an accuracy close to 100% has been developed by researchers from the CSIC, in collaboration with the hospitals of La Princesa and La Paz. The Spanish biotechnology company Immunostep produces and commercializes the test.

CSIC researchers have patented a gut bacteria called Christensenella minuta that has therapeutic applications to treat mood disorders, such as depression and anxiety. This technology has been developed by a team at the Institute of Agrochemistry and Food Technology (IATA-CSIC), and has has already been licensed to LNC Therapeutics, a French biotechnology company specialized in research and development of drugs in the area of ​​the intestinal microbiome.

Scientists from the IQAC-CSIC have participated in the development and essay of a molecule for fighting colon cancer metastasis. It is the first drug worldwide that blocks metastasis dissemination, which is the main cause of mortality of oncological patients. Also, the study demonstrates that the drug is less toxic and therefore reduces the adverse effects derived from conventional treatments.